Adolescent GLP 1s: The Muscle Gap

A 2026 perspective on GLP 1 therapy in adolescents raises a question that the main obesity trials were not designed to answer: what happens to musculoskeletal development and physical function while weight falls? The authors focus on medicines including semaglutide and liraglutide. They argue that treatment can reduce pain and mechanical load. It may ease other barriers to movement as well. Rapid weight loss during adolescence may also limit gains in lean tissue and bone. Long term pediatric data that can settle that concern remain limited^[1].

The clearest adolescent semaglutide result still comes from STEP TEENS. The randomized trial enrolled 201 participants aged 12 to under 18 years. At week 68, mean body mass index fell 16.1% with semaglutide plus lifestyle intervention and rose 0.6% with placebo plus lifestyle intervention^[2]. That efficacy result is substantial. It also explains why body composition and physical function deserve direct measurement rather than assumption.

The trial result and the missing measures

STEP TEENS was a double blind, randomized, placebo controlled trial. Participants received semaglutide or placebo alongside lifestyle intervention for 68 weeks. The primary outcome was percentage change in body mass index, and the confirmatory secondary outcome was loss of at least 5% of body weight. The trial reported that 73% of participants assigned semaglutide lost at least 5% of body weight, compared with 18% assigned placebo^[2].

The same publication reported improvements in waist circumference, glycated hemoglobin, most measured lipids, and alanine aminotransferase. Gastrointestinal adverse events occurred in 62% of the semaglutide group and 42% of the placebo group. Five semaglutide participants had gallstones, compared with none in the placebo group^[2]. These are useful efficacy and safety findings, but they do not tell readers whether adolescents preserved strength and added the expected amount of muscle. They also do not show whether participants reached expected gains in bone mineral content during treatment.

That distinction frames the 2026 perspective. Adolescence is a period of active musculoskeletal development, so a stable scan or strength score can carry a different meaning than it would in a fully grown adult. The authors warn that weight loss associated with GLP 1 therapy may attenuate muscle and bone accrual. They describe reduced peak musculoskeletal capacity and later frailty as plausible risks, while also stating that longitudinal pediatric evidence is limited^[1]. The paper presents a clinical concern and a research agenda. It does not report a new trial or prove that semaglutide damages adolescent bone or muscle.

Movement may become easier during treatment

Lower body mass can make movement less painful and reduce the mechanical work of daily activity. The perspective also points to psychosocial barriers that may ease when treatment is effective. For some adolescents, the period after treatment begins may therefore be a practical chance to build an activity routine that was difficult before. The authors want clinicians to treat improved mobility as an opening for supported movement, rather than assuming that weight loss by itself protects future physical function^[1].

Exercise evidence from children offers a reason to study that approach directly. In one school based randomized study, 57 children entered long term follow up after a seven month jumping program or a stretching control. The jumping group had 3.6% more hip bone mineral content after the intervention and 1.4% more after nearly eight years, after adjustment for age, height, weight, and physical activity^[3]. The study involved prepubertal children and did not involve GLP 1 therapy, so it cannot predict an outcome for adolescents taking semaglutide. It does show that loading exercise during growth can produce a measurable bone effect that persists.

The perspective recommends developmentally appropriate resistance exercise and weight bearing activity. It also recommends nutrition that provides adequate protein. Those proposals are meant to support lean mass and bone while treatment continues. They are not a universal exercise or food prescription. The authors call for plans tailored to the adolescent. Access and personal preferences are part of that decision, along with clinical circumstances^[1]. Families should discuss any training or nutrition change with the treating clinical team, especially when pain, mobility limits, disordered eating, or another health condition is present.

What clinicians still need to measure

Future pediatric trials need outcomes that separate total weight loss from developmental health. Body composition can estimate changes in fat and lean tissue. Bone imaging can follow mineral accrual. Strength tests, walking tests, and activity measures can show whether day to day function improves. Repeated measurements after treatment would help distinguish a temporary change from a lasting difference in development. The perspective calls for longitudinal research because current pediatric evidence does not yet provide those answers^[1].

Trials also need to report puberty stage, sex, baseline activity, dietary intake, and the amount and pace of weight loss. These factors can affect muscle and bone development and may change how a group average should be read. STEP TEENS gives a strong estimate of BMI change over 68 weeks, but its abstracted outcomes cannot answer whether an individual adolescent gained the expected muscle or bone during that period^[2]. A dedicated musculoskeletal endpoint would be more informative than trying to infer function from body mass index.

What this means for families

The evidence supports two facts at once. Semaglutide produced a large average reduction in body mass index in adolescents with obesity in a randomized trial^[2]. Researchers have not yet established the long term effects of GLP 1 associated weight loss on peak musculoskeletal capacity and physical function during adolescence^[1]. Concern about that gap should prompt monitoring and better trials, not claims of harm that the available studies have not demonstrated.

Readers can review our semaglutide evidence overview and the semaglutide regulation summary for the broader evidence and current prescription status. For an adolescent already receiving a GLP 1 medicine, the practical discussion with the treating team should include strength and movement. Food intake, symptoms, and development also belong beside the number on the scale. The next generation of trials should measure those outcomes directly.